Table 1.
Baseline characteristics of all patients
| Variable | Total (n=1,033) | Surgery group (n=765) | CRT group (n=268) | P-value |
|---|---|---|---|---|
| Age (yr) | 0.979 | |||
| ≥60 | 431 (41.7/100) | 319 (41.7/74.0) | 112 (41.8/26.0) | |
| <60 | 602 (58.3/100) | 446 (58.3/74.1) | 156 (58.2/25.9) | |
| Sex | 0.007* | |||
| Male | 859 (83.2/100) | 622 (81.3/72.4) | 237 (88.4/27.6) | |
| Female | 174 (16.8/100) | 143 (18.7/82.2) | 31 (11.6/17.8) | |
| T stage | 0.116 | |||
| Non T4a | 582 (56.3/100) | 442 (57.8/75.9) | 140 (52.2/24.1) | |
| T4a | 451 (43.7/100) | 323 (42.2/71.6) | 128 (47.8/28.4) | |
| N stage | 0.056 | |||
| N0–1 | 201 (19.5/100) | 160 (20.9/79.6) | 41 (15.3/20.4) | |
| N2 | 832 (80.5/100) | 605 (79.1/72.7) | 227 (84.7/27.3) | |
| Follow-up period (mo) | 31 (12–132) | 33 (12–122) | 23 (12–132) | 0.004* |
Values are presented as number of patients (%within group/%within variable) or median (range).
Surgery group, patients treated primarily by surgery with curative intent with/without (neo)adjuvant treatment; CRT group, patients treated primarily with chemotherapy and radiotherapy.
*
Statistically significant (P<0.05).